Cellectis S.A. (CLLS): +18% Surge in 30 Days Amid Strong Clinical Data and Earnings
Key Takeaways
- CLLS stock rose +18% over the last 30 days, driven by positive interim clinical data from partnered programs and strong Q4 2025 earnings beat.
- Over the past quarter, shares declined -5%, reflecting biotech sector volatility amid ongoing arbitration resolutions and pipeline developments.
- Key catalysts include April 2026 cema-cel trial data showing superior MRD clearance and March earnings with revenue beats and cash runway into 2027.
- Analyst sentiment remains positive with reiterated buy ratings, supporting recent price momentum.
- Macro biotech trends and partnerships with Allogene and AstraZeneca bolster fundamentals.
Understanding Cellectis S.A. (CLLS) and Its Place in Biotech
Cellectis S.A. is a clinical-stage biotechnology company pioneering gene-editing technologies to develop life-saving cell and gene therapies, primarily in immuno-oncology. Its core business model revolves around its proprietary TALEN® gene-editing platform to create allogeneic CAR-T (chimeric antigen receptor T-cell) therapies, which are off-the-shelf treatments derived from healthy donor cells rather than patient-specific autologous cells. This approach aims to reduce manufacturing time and costs compared to personalized therapies.
In the competitive gene-editing and CAR-T landscape, Cellectis holds a strong position through partnerships like those with Allogene Therapeutics for cema-cel and AstraZeneca for research collaborations. From what I see, its exposure to high-value milestones and royalties from partnered programs explains recent stock resilience, as positive clinical readouts directly enhance revenue potential and validate the platform's efficacy.
Recent Stock Performance: +18% in 30 Days Versus -5% Quarterly Decline
Over the last 30 days, CLLS stock advanced approximately +18%, from a close of $3.45 around mid-March to $4.07 recently. The movement was volatile yet trend-driven, with a sharp uptick in early April tied to clinical news, pushing shares above the 50-day moving average of $3.61 amid elevated volume. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
For the quarter, shares fell -5%, from $4.27 in mid-January to current levels. Performance was range-bound early on, with dips in March offset by late-quarter recovery, reflecting high beta (2.71) sensitivity to biotech market trends.
Key Drivers Behind the Recent 30-Day Rally in CLLS
The primary catalyst was April 13, 2026, interim data from Allogene's ALPHA3 pivotal trial of cema-cel, an allogeneic CAR-T licensed from Cellectis. Results showed 58.3% MRD (minimal residual disease) negativity at Day 45 versus 16.7% in the observation arm—a 41.6% absolute difference exceeding the 25-30% benchmark for clinical meaningfulness. No cytokine release syndrome (CRS), ICANS (immune effector cell-associated neurotoxicity syndrome), or graft-versus-host disease (GvHD) occurred, with most patients outpatient-managed. This validated Cellectis' platform, triggering a volume surge (9.5x average) and price jump.
Clear Street's reaffirmed Buy rating in late March further supported sentiment. Sector tailwinds in gene-editing amid positive peer data (e.g., Allogene's rally) amplified the move. One thing that stands out is how these developments align with broader trends I'm tracking in the space.
What Shaped CLLS Performance Over the Past Quarter
The quarter's -5% decline stemmed from broader biotech pressures, including high interest rates curbing risk appetite and pipeline uncertainties. A partial offset came from March 19-20, 2026, Q4/full-year 2025 earnings: revenue hit $79.6M (up from $49.2M prior year, driven by AstraZeneca collaboration), EPS beat estimates (-$0.19 vs. -$0.29), with $211M cash providing runway into H2 2027. However, net loss of $67.6M and revenue growth slowdown (-19.5% quarterly) weighed on sentiment.
December 2025 Servier arbitration partially terminated a license but opened direct talks with Allogene, limiting downside. Institutional focus on cash burn and macro conditions dominated, with high short interest (0.52%) adding pressure. In my view, the cash position remains a key strength here.
Trending AI Robots
I regularly turn to Tickeron’s Trending AI Robots page to stay ahead in my analysis—it showcases the platform's top-performing AI trading bots from hundreds available, scanning thousands of tickers across strategies like swing trading, trend-following, and scalping. These curated bots are selected based on recent performance metrics such as win rate, profit factor, and drawdown, with varying timeframes from intraday to long-term holds. Users can review detailed stats, backtests, and live signals to integrate into their trading. I find it particularly useful for discovering bots tailored to current market trends and enhancing my stock analysis workflow.
Looking Ahead: Key Drivers for CLLS Stock
Investors should monitor Allogene's ALPHA3 full readout (mid-2027 EFS interim), potential milestone payments from partnerships, and eti-cel Phase 1 NHL data (late 2025 updates). Upcoming earnings, FDA interactions for pivotal trials, and AstraZeneca collaboration progress are key. Macro factors like interest rates and biotech funding environment, plus Servier arbitration follow-ons, could sway sentiment. Risks include clinical setbacks or dilution; catalysts involve positive MRD data expansion and new deals. I'm watching these closely, as they could significantly influence the trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
```CLLS in upward trend: price expected to rise as it breaks its lower Bollinger Band on June 22, 2026
CLLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 35 cases where CLLS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLLS's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for CLLS just turned positive on June 30, 2026. Looking at past instances where CLLS's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLLS advanced for three days, in of 224 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day moving average for CLLS crossed bearishly below the 50-day moving average on May 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CLLS entered a downward trend on June 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.735) is normal, around the industry mean (20.977). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). CLLS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (4.158) is also within normal values, averaging (366.956).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CLLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a genome engineering company of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers
Industry Biotechnology
Advertisement